Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Gains from Investment Securities: 2021-2025

  • Prime Medicine's Gains from Investment Securities rose 86.40% to $83.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $132.0 million, marking a year-over-year increase of 173.67%. This contributed to the annual value of $44.9 million for FY2024, which is 1276.26% up from last year.
  • Per Prime Medicine's latest filing, its Gains from Investment Securities stood at $83.8 million for Q1 2025, which was up 86.40% from $44.9 million recorded in Q1 2024.
  • In the past 5 years, Prime Medicine's Gains from Investment Securities registered a high of $83.8 million during Q1 2025, and its lowest value of -$1.7 million during Q1 2023.
  • Its 3-year average for Gains from Investment Securities is $33.0 million, with a median of $25.0 million in 2023.
  • Per our database at Business Quant, Prime Medicine's Gains from Investment Securities tumbled by 82.62% in 2023 and then surged by 2,741.68% in 2024.
  • Prime Medicine's Gains from Investment Securities (Quarterly) stood at $2.2 million in 2021, then reached $17,000 in 2022, then crashed by 82.62% to $5.0 million in 2023, then surged by 2,741.68% to $44.9 million in 2024, then spiked by 86.40% to $83.8 million in 2025.
  • Its Gains from Investment Securities was $83.8 million in Q1 2025, compared to $44.9 million in Q1 2024 and $5.0 million in Q2 2023.